Part D plan sponsors needed to apply to participate in the model by April 20, 2026
People with type 2 diabetes have historically lost less weight on obesity medications than those without diabetes, Dr
4/ My Microdosing Protocol To evaluate the potential benefits I will start a 12 week trial of the GLP-1/GIP RA Tirzepatide (Commercial name: Munjaro for diabetes, Zepbound for weight loss)
The first generation of GLP-1 therapies exhibit reduced susceptibility to enzymatic degradation, while providing effective glucose control, improved -cell function, body weight loss and decreased systolic blood pressure in patients with T2D (Meier, 2012) The newly developed incretin mimetics, including albiglutide, dulaglutide and semaglutide, are designed to have extended pharmacokinetic profiles and efficacy suitable once-weekly administration
Why weight loss alone isnt a marker of health